scispace - formally typeset
B

Betty Chan

Researcher at Genentech

Publications -  11
Citations -  2105

Betty Chan is an academic researcher from Genentech. The author has contributed to research in topics: B-cell activating factor & Gene. The author has an hindex of 10, co-authored 10 publications receiving 2046 citations.

Papers
More filters
Journal ArticleDOI

FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family

TL;DR: Bronchoalveolar lavage fluid from mice with experimentally induced allergic pulmonary inflammation contains a novel 9.4 kDa cysteine‐rich secreted protein, FIZZ1, which may modulate the function of neurons innervating the bronchial tree, thereby altering the local tissue response to allergic pulmonaryinflammatory.
Journal ArticleDOI

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.

TL;DR: A critical role for BR3 in B cell ontogeny is underscored by data showing that the BR3 gene had been inactivated by a discrete, approximately 4.7 kb gene insertion event that disrupted the 3' end of theBR3 gene in A/WySnJ mice, which lack peripheral B cells.
Journal ArticleDOI

Activation and accumulation of B cells in TACI-deficient mice

TL;DR: TACI may play an unexpected inhibitory role in B cell activation that helps maintain immunological homeostasis in mice that were deficient in TACI.
Journal ArticleDOI

TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice.

TL;DR: It is shown here that TACI-Fc blocks the activation of T cells in vitro and inhibits antigen-specific T cell activation and priming in vivo and in a mouse model for rheumatoid arthritis, treatment substantially inhibited inflammation, bone and cartilage destruction and disease development.
Journal ArticleDOI

Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of Allergic Asthma

TL;DR: The therapeutic potential of blocking T-lymphocyte costimulation by CTLA4-IgG as a possible immunosuppressive treatment for patients with allergic asthma is indicated.